Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LYRA 
Lyra Therapeutics Inc (LYRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LYRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.5
1 Year Target Price $11.5
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 5.96% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.76M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 4 | Beta 0.12 | 52 Weeks Range 3.81 - 34.00 | Updated Date 10/17/2025 |
52 Weeks Range 3.81 - 34.00 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -28.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4605.46% |
Management Effectiveness
Return on Assets (TTM) -30.4% | Return on Equity (TTM) -238.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14451846 | Price to Sales(TTM) 16.06 |
Enterprise Value 14451846 | Price to Sales(TTM) 16.06 | ||
Enterprise Value to Revenue 18.45 | Enterprise Value to EBITDA 0.66 | Shares Outstanding 1644454 | Shares Floating 1122307 |
Shares Outstanding 1644454 | Shares Floating 1122307 | ||
Percent Insiders 0.67 | Percent Institutions 38.1 |
Upturn AI SWOT
Lyra Therapeutics Inc
Company Overview
History and Background
Lyra Therapeutics, Inc. was founded in 2003. It is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of ear, nose, and throat (ENT) diseases.
Core Business Areas
- ENT Therapies: Lyra Therapeutics develops bioresorbable, sustained-release drug delivery platforms for treating ENT diseases such as chronic rhinosinusitis (CRS).
Leadership and Structure
The leadership team includes individuals with experience in pharmaceuticals, medical devices, and finance. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- LYR-210: LYR-210 is an investigational, bioresorbable matrix designed to deliver mometasone furoate directly to the sinuses for up to six months for the treatment of chronic rhinosinusitis (CRS). This product is currently in clinical trials. There is no current market share or revenue data, as it is not yet approved for commercial use. Competitors include nasal corticosteroids sprays, oral steroids, antibiotics and surgical interventions for CRS.
- LYR-220: LYR-220 is an investigational, bioresorbable matrix also delivering mometasone furoate, but with a modified design for potentially broader applicability in CRS patients. This is also in clinical trials, and lacks market data and revenue. Competitors are similar to LYR-210, namely nasal corticosteroids sprays, oral steroids, antibiotics and surgical interventions for CRS.
Market Dynamics
Industry Overview
The ENT therapeutics market is characterized by unmet needs in chronic conditions such as rhinosinusitis, driving demand for novel drug delivery systems and therapies.
Positioning
Lyra Therapeutics aims to establish itself as a leader in localized drug delivery for ENT diseases, leveraging its proprietary bioresorbable matrix technology. It's a niche player focused on sustained drug release.
Total Addressable Market (TAM)
The chronic rhinosinusitis market is estimated to be multi-billion dollars. Lyra is aiming to capture a significant share of this market with its sustained-release products, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary bioresorbable matrix technology
- Localized and sustained drug delivery
- Potential to reduce systemic side effects compared to oral medications
- Focus on unmet needs in ENT diseases
Weaknesses
- Clinical-stage company with no currently approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources
- Concentration of risk in a few key product candidates
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion to other ENT indications
- Acquisition by a larger player in the ENT space
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ENTX
- ALKS
- REGN
Competitive Landscape
Lyra is a niche player focusing on localized drug delivery in ENT. Competitors include established pharmaceutical companies with broader product portfolios. Lyra's competitive advantage lies in its proprietary technology for sustained drug release.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D spending and clinical trial activity.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approval, and commercialization of LYR-210 and LYR-220. Analyst estimates are variable and dependent on clinical progress.
Recent Initiatives: Recent initiatives include advancing LYR-210 and LYR-220 through clinical trials and exploring potential partnerships.
Summary
Lyra Therapeutics is a high-risk, high-reward clinical-stage company. Its strengths lie in its innovative drug delivery technology, but it faces significant risks related to clinical trial outcomes and regulatory approval. Positive clinical data could lead to substantial gains, while setbacks could negatively impact the company's prospects. The company is focused on unmet needs with ENT therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lyra Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lyra Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-05-01 | CEO, President & Chairman Dr. Maria Palasis Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://lyratherapeutics.com |
Full time employees 30 | Website https://lyratherapeutics.com | ||
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.